Vernalis PLC Share News (VER)

UPDATE: Backed By CEO And Investors, Vernalis Raises GBP40 Million (ALLISS)

Vernalis Eyes US Cough Cold Market With GBP40 Million Fundraising (ALLISS)

Vernalis hires AstraZeneca marketeer to lead Tuzistra operation in US

(ShareCast News) - Vernalis has appointed 24-year AstraZeneca veteran Sandford 'Sandy' Sommer as president and chief operating officer of its US operation, Vernalis Therapeutics. Sommer most recent role was as president of AstraZeneca's Colombia operations, following a variety of leadership roles, i

Vernalis Taps AstraZeneca Veteran Sommer For US Business

Vernalis Says CCP-07 Study Completed, On Track For Application

Vernalis Completes Single-Dose Study For Cough And Cold Product

Vernalis drops into red after investment in cough treatment

(ShareCast News) - Shares in Vernalis sank to an 11-month low after the biotech company posted a half-year loss as its first prescription cough cold product, Tuzistra XR, launched during what has proved a very mild flu season in the USA. Revenue was up 7% to £6.1m in the six months to 31 December, b

Vernalis Interim Loss Widens As Spending Rises On Launch Of Tuzistra

Earnings, Trading Statements Calendar - Week Ahead

Vernalis Reveals US-Based Corvus Pharmaceuticals As Licensee

Vernalis Says Cough Cold Drug CCP-07 Completes Single-Dose Study

Vernalis Confident After Tuzistra Launch And Moxatag Acquisition

AGM, EGM Calendar - Week Ahead

Vernalis Says Tris Pharma Begins Stability Testing Of CCP-08

Vernalis acquires rights to Pragma's MOXATAG treatment

(ShareCast News) - Pharmaceutical group Vernalis has completed the acquisition of the US rights to the amoxicillin extended-release tablet brand MOXATAG from Pragma Pharmaceuticals. The London-listed company said it has made an undisclosed up-front payment in cash for the rights, with a further paym